sb 203580 has been researched along with fedratinib in 4 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (fedratinib) | Trials (fedratinib) | Recent Studies (post-2010) (fedratinib) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 120 | 16 | 111 |
| Protein | Taxonomy | sb 203580 (IC50) | fedratinib (IC50) |
|---|---|---|---|
| Cyclin-G-associated kinase | Homo sapiens (human) | 0.001 | |
| Tyrosine-protein kinase JAK2 | Homo sapiens (human) | 0.0035 | |
| Bromodomain-containing protein 4 | Homo sapiens (human) | 0.29 | |
| Proto-oncogene tyrosine-protein kinase receptor Ret | Homo sapiens (human) | 0.0325 | |
| Tyrosine-protein kinase JAK1 | Homo sapiens (human) | 0.053 | |
| Non-receptor tyrosine-protein kinase TYK2 | Homo sapiens (human) | 0.078 | |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 0.02 | |
| Tyrosine-protein kinase JAK3 | Homo sapiens (human) | 0.3917 | |
| AP2-associated protein kinase 1 | Homo sapiens (human) | 0.032 | |
| Bromodomain testis-specific protein | Homo sapiens (human) | 0.34 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Munoz, L | 1 |
| Bharate, SB; Raghuvanshi, R | 1 |
1 review(s) available for sb 203580 and fedratinib
| Article | Year |
|---|---|
Non-kinase targets of protein kinase inhibitors.
Topics: Animals; Drug Design; Drug Evaluation, Preclinical; Humans; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Kinases | 2017 |
3 other study(ies) available for sb 203580 and fedratinib
| Article | Year |
|---|---|
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |